Yamada S, Ohkura T, Yamadera T, Ito O, Kimura R, Nozawa Y, Hayashi S, Miyake H
Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Taiho Pharmaceutical Company, Ltd., Tokushima, Japan.
J Pharmacol Exp Ther. 1997 Dec;283(3):1389-95.
The catecholaminergic neuronal activity and the densities of alpha-1 and beta adrenoceptors and angiotensin II receptors were simultaneously determined in BIO 53.58, a model of idiopathic dilated cardiomyopathy, and F1B control hamsters. Further, we examined the effect of repeated p.o. administration of metoprolol on these biochemical parameters. Compared with F1B control hamsters, there was a significant decrease in Bmax of specific binding of both (-)-[125I]iodocyanopindolol and [3H]prazosin with a marked elevation of plasma catecholamine (mainly norepinephrine and epinephrine) concentrations, in BIO 53.58 hamsters at 11 and 18 weeks of age (severe cardiomyopathic stage), but not at 5 weeks of age. On the other hand, the Bmax value of myocardial [125I]angiotensin II binding in BIO 53.58 hamsters was almost identical to that in F1B hamsters. These results suggest a development of down-regulation of myocardial beta and alpha-1 adrenoceptors because of an increased catecholaminergic neuronal activity with aging in BIO 53.58 hamsters. Repeated p.o. administration of a relatively low dose (1 mg/kg/day) of metoprolol for 7 weeks in 11-week-old BIO 53.58 hamsters caused a significant increase of myocardial (-)-[125I]iodocyanopindolol binding sites with a marked reduction in plasma catecholamine levels; this indicated a significant recovery to the F1B levels. The improvement of these biochemical parameters by metoprolol treatment was also accompanied by a significant decrease in the fibrosis in the heart in BIO 53.58 hamsters. These data suggest that catecholaminergic neurons and adrenoceptors play a part in the development of heart failure in idiopathic dilated cardiomyopathy. Consequently, the present study may provide a further pharmacological basis for the use of beta-1 adrenoceptor antagonists in patients with idiopathic dilated cardiomyopathy.
在特发性扩张型心肌病模型BIO 53.58仓鼠和F1B对照仓鼠中,同时测定了儿茶酚胺能神经元活性、α-1和β肾上腺素能受体以及血管紧张素II受体的密度。此外,我们研究了口服美托洛尔对这些生化参数的影响。与F1B对照仓鼠相比,11周和18周龄(严重心肌病阶段)的BIO 53.58仓鼠,(-)-[125I]碘氰吲哚洛尔和[3H]哌唑嗪特异性结合的Bmax显著降低,血浆儿茶酚胺(主要是去甲肾上腺素和肾上腺素)浓度显著升高,但5周龄时未出现这种情况。另一方面,BIO 53.58仓鼠心肌[125I]血管紧张素II结合的Bmax值与F1B仓鼠几乎相同。这些结果表明,由于BIO 53.58仓鼠随着年龄增长儿茶酚胺能神经元活性增加,心肌β和α-1肾上腺素能受体发生了下调。在11周龄的BIO 53.58仓鼠中,口服相对低剂量(1mg/kg/天)的美托洛尔7周,导致心肌(-)-[125I]碘氰吲哚洛尔结合位点显著增加,血浆儿茶酚胺水平显著降低;这表明显著恢复到了F1B水平。美托洛尔治疗改善这些生化参数的同时,BIO 53.58仓鼠心脏的纤维化也显著减少。这些数据表明,儿茶酚胺能神经元和肾上腺素能受体在特发性扩张型心肌病心力衰竭的发生中起作用。因此,本研究可能为特发性扩张型心肌病患者使用β-1肾上腺素能受体拮抗剂提供进一步的药理学依据。